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ABSTRACT
Deoxyuridine triphosphate nucleotidohydrolase
(dUTPase) catalyzes the hydrolysis of dUTP to
dUMP and PPi. Although dUTP is a normal intermedi-
ate in DNA synthesis, its accumulation and misincor-
poration into DNA is lethal. Importantly, uracil
misincorporation is a mechanism of cytotoxicity
induced by fluoropyrimidine chemotherapeutic
agents including 5-fluorouracil (5-FU) and elevated
expression of dUTPase is negatively correlated
with clinical response to 5-FU-therapy. In this study
we performed the first functional characterization of
the dUTPase promoter and demonstrate a role for
E2F-1 and Sp1 in driving dUTPase expression.
We establish a direct role for both mutant and
wild-type forms of p53 in modulating dUTPase pro-
moter activity. Treatment of HCT116 p53
+/+ cells
with the DNA-damaging agent oxaliplatin induced
a p53-dependent transcriptional downregulation
of dUTPase not observed in the isogenic null cell
line. Oxaliplatin treatment induced enrichment of
p53at the dUTPase promoter with a concomitant
reduction in Sp1. The suppression of dUTPase by
oxaliplatin promoted increased levels of dUTP that
was enhanced by subsequent addition of fluoropy-
rimidines. The novel observation that oxaliplatin
downregulates dUTPase expression may provide
a mechanistic basis contributing to the synergy
observed between 5-FU and oxaliplatin in the clinic.
Furthermore, these studies provide the first evi-
dence of a direct transcriptional link between the
essential enzyme dUTPase and the tumor suppres-
sor p53.
INTRODUCTION
Deoxyuridine triphosphate nucleotidohydrolase (dUT
Pase) is the sole enzyme responsible for the hydrolysis of
dUTP to dUMP and pyrophosphate simultaneously pro-
viding substrate for thymidylate synthase (TS) and elim-
inating dUTP from the DNA biosynthetic pathway.
Although dUTP is a normal intermediate in DNA synth-
esis, its extensive accumulation and misincorporation
into DNA is lethal in both prokaryotic and eukaryotic
organisms as evidenced from knockout models (1,2).
Importantly, uracil misincorporation also represents
a major mechanism of cytotoxicity induced by the
TS-inhibitor class of chemotherapeutic agents including
the ﬂuoropyrimidines 5-ﬂuorouracil (5-FU), ﬂuorodeox-
yuridine (FUdR) and capecitabine which are broadly
used in the treatment of cancers of the gastrointestinal
tract, breast and head and neck (3). Inhibition of TS
induces a metabolic blockade, depleting thymidylate
pools and in some instances promoting the accumulation
of intracellular dUTP pools and subsequent misincorpora-
tion of uracil into DNA resulting in DNA damage and cell
death (4,5). Expression of dUTPase is reported to be an
important mediator of resistance to therapeutic agents
that target TS both in vitro and in vivo. We previously
demonstrated that diminished dUTPase expression greatly
enhanced dUTP pool expansion following TS-inhibition,
sensitizing yeast cells to the eﬀects of uracil misincorpora-
tion while cells overexpressing dUTPase were signiﬁcantly
protected (6). In colon cancer cells, depletion of dUTPase
by siRNA resulted in dUTP accumulation and growth
arrest (7). Overexpression of dUTPase was also demon-
strated to confer resistance to FUdR (8), while we pre-
viously reported that depletion of dUTPase by siRNA
sensitized both breast and colon cell lines to FUdR
through misincorporation of dUTP and enhanced DNA
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a retrospective clinical study negatively correlating
elevated nuclear expression of dUTPase with response to
5-FU-therapy in colorectal cancer patients (10). These
studies bolster the concept that dUTPase represents an
attractive drug target and we recently reported the identi-
ﬁcation of novel small molecules with dUTPase inhibitory
activity (11).
While detailed analyses of dUTPase structure and
catalytic activity have been described, the mechanisms
that govern human dUTPase gene regulation and expres-
sion remain largely unknown (12–14). Previous
studies have reported that expression of the nuclear iso-
form of dUTPase (DUT-N) is primarily cell cycle and
proliferation-dependent, whereas the mitochondrial iso-
form (DUT-M) is constitutively expressed (15). Immuno-
histochemical staining of normal tissues demonstrated
that high DUT-N expression is exclusively observed in
replicating cell types whereas cytoplasmic expression is
observed in mitochondria-rich tissues (10). However,
both colon cancer cell lines (16) and tumor specimens
demonstrate dramatic variation, both in magnitude of
dUTPase expression and intracellular localization.
Furthermore, the correlation between replication status
and DUT-N expression was not observed in colon adeno-
carcinomas (17). Importantly, dysregulation of dUTPase
expression is observed in tumor types which are frequently
treated with agents that target TS, therefore elucidating
the molecular basis driving dUTPase expression is impor-
tant from both a basic science and clinical standpoint
(10,16,17). Functional analyses of various S-phase-speciﬁc
genes including TS and thymidine kinase (TK) identiﬁed
several transcriptional elements that are commonly pre-
sent in their promoter regions including E2F and Sp1
consensus sites. These genes are also characterized by a
lack of TATA or CAAT box initiation sites, but are rich in
GC boxes. Promoter sequence analysis of the DUT gene
reveals putative regulatory motifs including potential
binding sites for NF-kB, E2F and Sp1 transcription fac-
tors (15). Recently, a genome-wide ChIP-on-chip identi-
ﬁed dUTPase in a subset of 127 genes bound by E2F
family members (18). Despite the presence of these puta-
tive S-phase-speciﬁc binding sites in the DUT-N promoter
region, functional analysis of this gene has not been pre-
viously reported.
Several studies have also reported downregulation of
dUTPase during apoptosis (19,20) and that dUTPase
expression may be modulated by the tumor suppressor
gene p53 (21,22). In response to stress stimuli such as
DNA damage, p53 can initiate cell cycle arrest through
transcriptional induction of cell cycle inhibitors such as
p21
cip1/waf1, mediate DNA repair or induce apoptotic
cell death. These mechanisms are designed to prevent pro-
liferation of cells containing damaged DNA and reduce
the likelihood of tumor formation. Interestingly, muta-
tions in p53 are one of the most common genetic aberra-
tions detected in malignant disease with >50% of colon
tumors exhibiting mutation (23).
In prostate cancer cells, dUTPase was one of many
genes identiﬁed by microarray analysis as signiﬁcantly
repressed following introduction of wild-type p53 (22).
In MCF-7 (p53 wild-type) breast cancer cells, microarray
analysis also identiﬁed dUTPase mRNA within an exten-
sive panel of genes repressed following 5-FU treatment
(21). However, the precise mechanism of the downregula-
tion of dUTPase has not been determined and it is
unknown as to whether this phenomenon is the result of
indirect downstream events induced by p53 itself or its
transactivation and repressive gene targets. Furthermore,
dUTPase was one of a number of genes identiﬁed as
upregulated in p53-null mouse embryonic ﬁbroblasts fol-
lowing introduction of the human tumor-derived p53
R175H by subtraction hybridization (24).
As dUTPase is an essential enzyme in maintaining geno-
mic stability, and demonstrates both aberrant intratu-
moral expression and an association with resistance to
5-FU, we sought to perform the ﬁrst functional character-
ization of the promoter and elucidate the mechanisms
involved in regulating dUTPase expression. In addition,
p53 mutations are widely observed in many cancers and as
the ﬂuoropyrimidines remain the mainstay chemothera-
peutics in gastrointestinal cancer treatment, characterizing
a role for p53 in regulating dUTPase gene expression in
tumor cells may be of major clinical signiﬁcance and may
lead to more targeted therapeutic options. In this study,
we demonstrate direct roles for Sp1 and E2F-1 in driving
basal DUT-N expression and report a direct role for wild
type and mutant p53 in repressing and inducing dUTPase
promoter activity respectively. Furthermore, we demon-
strate the ability of oxaliplatin, an important chemother-
apeutic agent primarily used in combination with 5-FU in
the treatment of colorectal cancer, to acutely suppress the
dUTPase promoter, mRNA and protein expression and
enzymatic activity in a p53-dependent manner. We also
present evidence that p53 is associated with the endogen-
ous dUTPase promoter in vivo, and propose that inter-
ference with transcription machinery at the dUTPase
promoter by wild-type p53 represents a plausible mecha-
nism for this transcriptional repression. Finally, suppres-
sion of dUTPase by oxaliplatin resulted in the expansion
of intracellular dUTP pools and subsequently enhanced
the downstream eﬀects of TS-inhibition. This interaction
may contribute to the clinical synergy observed between
5-FU and oxaliplatin in the treatment of colorectal cancer.
MATERIALS AND METHODS
Compoundsand reagents
5-FU, ﬂuorodeoxyuridine (FUdR), paclitaxel, doxycycline
(DOX), G418 and mithramycin A were purchased from
Sigma (St Louis, MO). Oxaliplatin was obtained with per-
mission from Sanoﬁ Synthelabo (Bridgewater, NJ).
Cellculture
The human colon cancer cell lines HCT116 p53
+/+,
HCT116 p53
–/– and HCT116 p21
–/– cell lines, generated
via homologous recombination, were generous gifts from
the laboratory of Dr Bert Vogelstein at Johns Hopkins
University (Baltimore, MD). HCT116 cell lines were
grown in McCoy’s 5A. Drosophila SL2 cells (Invitrogen,
Carlsbad, CA) were grown in Schneider’s Insect media
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All other media was supplemented with 10% fetal bovine
serum (Lonza, East Rutherford, NJ) with penicillin/
streptomycin, and sodium pyruvate (Invitrogen). Cells
were maintained in a humidiﬁed Forma incubator
(Thermoscientiﬁc, Waltham, MA) at 378C with 5%
CO2. All cell lines were routinely screened for the presence
of mycoplasma using the MycoALERT assay (Lonza,
Rockland, ME).
Generationof overexpression constructs
The pPac0 and pPac-Sp1, pN3 empty vector (EV) and
pN3-Sp1 were a kind gift from Dr Guntram Suske from
the Institut Fur Molekularbiologie und Tumorforschung
(Marburg, Germany). Chemically synthesized primers
incorporating restriction endonuclease sites were used to
generate PCR fragments corresponding to the DUT-N
and p53 wild-type coding sequences from the HCT116
p53
+/+ cell line. Cloning was performed as previously
described (25). cDNA corresponding to the p53 R175H
mutant was generated using site-directed mutagenesis of
p53 wild type: 50-CGT TGT GAG GCA CTG CCC CCA
CC-30. Brieﬂy, The cDNA fragments were gel puriﬁed
using the QIAquick gel puriﬁcation kit (QIAGEN,
Valencia, CA) and ligated into the pre-digested pTRE-
Tight vector (BD Clontech, Mountainview, CA) for
DUT-N, and pCI-Neo for the p53 cDNA using standard
methods. Recombinant DNA was transformed into the
E. coli host strain DH5a, DNA isolated and analyzed by
restriction digest and sequenced for orientation and integ-
rity of the gene insert. Functionality of the nuclear
dUTPase (pTre-Tight:DUT-N), p53
WT (pCI-Neo:p53
WT)
and the p53 R175H mutant (pCI-Neo:p53
MUT) constructs
were conﬁrmed by transient transfection and Western
blotting (9).
Generationof theHCT116 pTet-Off cell line
HCT116 p53
+/+ cells were seeded at a density of 1 10
6
on a 10cm plate for 24h, transfected using Expressfect
TM
(Denville Scientiﬁc, Metuchen, NJ) with 2mg of the pTet-
Oﬀ plasmid (BD Clontech). Six hours post-transfection,
complexes were removed, cells were washed once with
PBS and fresh medium was added. After 24h, cells were
trypsinised into six 10cm plates for 24h before media
containing G418 (800mg/ml) was added. After selection
for approximately 14 days, colonies were isolated
and expanded. Potential pTet-Oﬀ cells were tested for
tetracycline-repressible expression by transient transfec-
tion with the pTre-Tight:Luc (BD Clontech) in media
containing 10% tet-approved FBS (BD Clontech) in the
presence and absence of DOX (500ng/ml).
Overexpression of dUTPase
HCT116 pTet-Oﬀ cells were seeded on 6cm plates and 3h
after plating the cells were washed with PBS and growth
media containing 10% tet-approved FBS (BD Clontech)
added. Cells were transfected after 24h with 2mg
pTre-Tight:DUT-N for 6h, washed in PBS and fresh
media added. Twenty-four hours post-transfection,
media containing the appropriate cytotoxic agent was
added. Cells were harvested for protein after 48h incuba-
tion and inducible expression of dUTPase conﬁrmed using
Western blotting and enzyme activity assay.
dUTPase promoter constructs
The 1.2kb region of the dUTPase promoter upstream of
the transcriptional start site was previously reported to
encompass all putative transcription factor-binding sites
with high correlation to reported consensus sequences
(15). This region was ampliﬁed by PCR using chemically
synthesized primers (50- GGT TCC CAC TGC GTT
TCT G; 30-CTC TCC TCT TCC CCC GGT G) and the
generated 1.231kb fragment cloned into the pGL3-Basic
immediately upstream of the ﬁreﬂy luciferase gene
and was termed the ‘full length’. Promoter truncations
were performed using the following primers followed by
re-ligation: pGL3:608 (50-CGA AGC CGC GGT ACT
CTC C-30), pGL3:162 (50-GAA GGG CTT CAA ACC
CAA AAT-30), pGL3:65 (50-GAA ATT TCG GTT TTG
GCG C-30).
Site-directed mutagenesis
Targeted site-speciﬁc mutagenesis of Sp1- and E2F-bind-
ing sites in the dUTPase promoter were performed using
the GeneEditor in vitro Site-Directed Mutagenesis System
(Promega, Madison, WI) according to manufacturer’s
instructions. Brieﬂy, the triple Sp1 mutant (pGL3:Sp1)
was generated by double base mutation from GG!TT
(underlined) within the Sp1 site indicated in bold, using
the following chemically synthesized primers, 50-GCT
GGC TTG AAA TTT CGG TTT TG-30,5 0-CTC GTC
CCG GGG AGG TTC GGT GGG TGG GGC GG-30,
50-TGG TTC GGG GCT GGC TTG AAA TTT CGG
TTT TG-30 in three consecutive rounds of mutagenesis.
The E2F mutant (pGL3:E2F) was generated by double
base mutation from CG!AT (underlined) within the E2F
site indicated in bold using 50-GAA ATT TCG GTT TTG
GAT CTC TCC CTG CGG C-30 (Supplementary
Figure 1). The integrity of each site-speciﬁc mutant was
conﬁrmed by direct DNA sequencing.
Antibodies and western blotting
At speciﬁed time points, cells were collected and anal-
yzed by western blot as described previously (9). Blots
were probed overnight at 48C with the following antibo-
dies from Santa Cruz Biotechnology (Santa Cruz, CA) at
speciﬁed dilutions: anti-p53 (1:2000), anti-p21 (1:1000),
anti-Sp1 (1:2000), anti-E2F-1 (1:1000) and anti-b-actin
(1:4000). Aﬃnity puriﬁed anti-dUTPase was used at
1:500 as previously described (26).
Growth inhibition assay
Cells were seeded in 96-well plates at 3 10
3 and exposed
to 5-FU, FUdR or oxaliplatin, alone and in combina-
tion for 72h. Growth inhibition was measured as pre-
viously described (9) using CellTiter 96 AQueous One
Solution (Promega). Absorbance was measured using a
SpectraMax 190 microplate reader (Molecular Devices,
Sunnyvale, CA) at 490nm. Fraction aﬀected (FA) was
80 Nucleic Acids Research, 2009, Vol. 37,No. 1calculated from the percent growth inhibition using the
following equation: (100 percent growth inhibition)/
100. Statistical signiﬁcance was determined using a two-
way ANOVA (Graphpad, San Diego, CA).
dUTP accumulation assay
HCT116 p53
+/+ cells were treated with speciﬁed concen-
trations of 5-FU, FUdR, paclitaxel and oxaliplatin or
combinations for indicated times, harvested and resus-
pended in PBS. Cells were analyzed for nucleotide pool
content using the assay developed by Sherman and Fyfe
(27) modiﬁed to detect levels of TTP and dUTP by pre-
incubating cellular extracts with recombinant dUTPase
(9,28). The amount of radioactive incorporation, mea-
sured in the presence of dUTPase represented the TTP
pool only, while untreated extracts represented both the
dUTP and TTP pools. The amount of dUTP accumula-
tion was determined by subtracting the results of extracts
treated with dUTPase from the untreated extracts and
presented as percentage accumulation in histogram
format. The diﬀerences between treatment groups were
analyzed for statistical signiﬁcance using a two-tailed
unpaired Student’s t-test (Graphpad).
dUTPase activity assay
Twenty-ﬁve micrograms of total protein was normal-
ized to a 20ml volume with PBS/protease inhibitor.
Relative dUTPase activity was determined as previously
described (9), and expressed as a percentage relative to the
appropriate untreated time-matched control.
RNA isolation, cDNA synthesis and quantitative real-time
RT–PCR (qPCR)
RNA was isolated using Trizol as per manufacturers
method (Invitrogen) and subjected to lithium chloride pre-
cipitation. cDNA was reverse transcribed using 200ng
total RNA following M-MLV-RT protocol (Invitrogen).
qPCR was conducted using the ABI 7500 (Applied
Biosystems, Foster City, CA) and Plexor
TM multiplex
(Promega). Probe sets used for qPCR analysis were as
follows: dUTPase 50-FAM
TM-iso-dC-GGG AGA TCA
TAT GAG TTA AAT ACA GGC TTT TTT T-30,
50-GGT GAC CTG ATG TAA ACA GTG TCT TC-30;
TS 50-Cal Fluor Orange 560-iso-dC-CCA TGT CTC
CCG ATC TCT GGT-30,5 0-TGG AAT CCA AGA
GAT CTT CCT CTG ATG-30; 18S 50-Cal Fluor
Red 610-iso-dC-GCA TCG TTT ATG GTC GGA
ACT ACG-30,5 0-TTG TTG GTT TTC GGA ACT
GAG GC-30. GAPDH is a pre-validated house-keeping
gene purchased with the Plexor
TM multiplex system and
was detected as Cal Fluor Red 610. Standard curves with
>0.95R
2 and PCR-eﬃciency at 100 2% were conﬁrmed
for each primer set within the multiplex. Threshold
cycle values (CT) were determined from three inde-
pendently isolated RNA samples and performed in tripli-
cate. dUTPase and TS mRNA expression levels were
determined by normalizing against both 18S and
GAPDH expression using the 2
–CT method (29) and
calibrated against appropriate time-matched controls.
mRNA expression is presented in a histogram as a per-
centage of the appropriate untreated time-matched
control. Statistical signiﬁcance was determined using a
two-tailed unpaired Student’s t-test (Graphpad).
Transient transfection and luciferase promoter assay
Drosophila SL-2 cells and HCT116 isogenic lines were
seeded in a 24-well plate. Transient transfections were
performed using plasmid DNA normalized to 0.25mg/ml
using Fugene
TM (Roche, Basel, Switzerland) for SL2 cells
and Expressfect
TM (Denville) for HCT116 cells, according
to manufacturer’s instructions. The dUTPase pGL3 pro-
moter constructs were transfected alone or co-transfected
with pCI-Neo:p53
WT, pCI-Neo:p53
MUT and the corre-
sponding pCI-Neo EV. Additional experiments were per-
formed by co-transfecting the appropriate dUTPase
promoter construct with the mammalian pN3-Sp1 or
pN3 EV constructs or the Drosophila pPac-Sp1 and
pPac0 constructs. All wells were transfected with 0.2mg
of the appropriate construct with co-transfections totaling
0.4mg DNA. The pRL-TK plasmid was included in all
transfections at a ratio of 1:10 (control:reporter) to
account for transfection eﬃciency. The pGL3-Basic EV
was also tested with all expression constructs and cyto-
toxic agents to discount non-speciﬁc eﬀects. Six hours
post-transfection, cells were washed with PBS and incu-
bated in either fresh media or media containing a cyto-
toxic agent at the appropriate concentration. After an
additional 30h, cells were washed once with PBS, lysed
and quantiﬁed as per western blotting methodology to
account for variation in cell number. Twenty-ﬁve micro-
grams of total protein was normalized to 20ml and ana-
lyzed using the dual-luciferase reporter assay (Promega) in
a TD 20/20 luminometer (Turner Biosystems, Sunnyvale,
CA). Three independent promoter experiments were per-
formed, each transfection in triplicate and the mean of two
ﬁreﬂy luminescence readings recorded, subsequently the
reaction was quenched and Renilla luciferase measured.
Co-transfection experiments investigating the eﬀects
of Sp1 overexpression were subject only to correction
for protein concentration due to non-speciﬁc eﬀects of
Sp1 on the pRL-TK vector. Histograms are presented as
normalized relative luciferase, or fold-change compared
to control as appropriate. The diﬀerences between
comparative transfections were analyzed for statistical sig-
niﬁcance using a two-tailed unpaired Student’s t-test
(Graphpad).
RNAi
Two million cells were plated for 24h and subsequently
transfected using Lipofectamine RNAiMax (Invitrogen)
alone (Mock) or with 100nM scrambled control siRNA
(Scr) or 100nM of validated Stealth
TM DuoPak siRNA
targeting Sp1 (Invitrogen). For western blotting, cells
were harvested after 72h for analysis of dUTPase, Sp1
and b-actin protein expression. For dUTPase promoter
activity, siRNA-transfected cells were trypsinised after
24h and re-plated in 24-well plates and allowed to
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dUTPase promoter for 30h.
Chromatin immunoprecipitation (ChIP)
Three million cells were plated for 24h and treated with
the appropriate cytotoxic agent for a further 12h. ChIP
was performed using the EZ-ChIP kit (Upstate/Millipore,
Temecula, CA) according to the manufacturers’ instruc-
tions. Brieﬂy, DNA-protein cross-linking was achieved by
addition of 1% formaldehyde to media. Cross-linked
chromatin was sonicated on ice to  200bp, veriﬁed by
gel electrophoresis, puriﬁed and incubated with 5mgo f
the appropriate ChIP-validated antibody: Sp1 5mg;
(Millipore), E2F-1 5mg, p53 5mg (Santa Cruz), by over-
night rotation at 48C, washed and cross-linking reversed.
Parallel IPs using the kit-supplied anti-acetyl H3 (Ac-H3)
and rabbit IgG as positive and negative controls respec-
tively were performed. For qPCR, recovered IP chromatin
and total input DNA were resuspended in 50mlo f
TE buﬀer. qPCR was performed using Dynamo SYBR
green (New England BioLabs, Beverly, MA), standard
PCR protocol and PCR primers ﬂanking the dUTPase
promoter (–39 to –260) generating a 221bp product
encompassing the triple Sp1 sites and E2F site: Upper
50-CAC CAG AAC TGT GGA CTC GT-30. Lower
50-CAG GGA GCG CGC CAA AAC CG-30
(Figure 1A). Threshold cycle values (CT) were determined
in triplicate for each treatment from two independent IP
samples, calibrated against input and compared to control
IgG using the following equation:
Ab of interest ChIP relative to control ChIP2
¼ 2½CTðIgG controlÞ CTðSp1=E2F 1=p53=Ac H3Þ 
where CT=CT(IP sample) – CT(DNA input).
Changes in promoter enrichment for Ac-H3, Sp1, E2F
and p53 following drug treatment are expressed as fold
enrichment over control IgG or fold increase compared
to untreated time-matched controls where appropriate
with diﬀerences between ChIPs analyzed for statistical sig-
niﬁcance using a two-tailed unpaired Student’s t-test
(Graphpad). Semi-quantitative ChIP analysis was per-
formed using the same primers, standard three-step PCR
ampliﬁcation with products visualized by gel electropho-
resis. As a control, IP DNA was subjected to PCR using
primers targeting the dUTPase ORF to verify ampliﬁca-
tion only in ‘input’ DNA.
Electrophoretic mobility shiftassay(EMSA)
Electrophoretic mobility shift analyses were performed
as described earlier with minor modiﬁcation (30). Synthetic
double-stranded oligonucleotides (Integrated DNA Tech-
nologies, Coralville, IA) corresponding to the –64 to –91
from the DUT-N transcriptional start site and encompass-
ing the triple Sp1 site were labeled with [
32P]ATP (Amer-
sham Pharmacia Biotech) according to the Gel-Shift Assay
Kit protocol (Promega). For each gel shift reaction,
10000cpm of labeled probe were incubated with
Figure 1. Systematic analysis of dUTPase gene promoter. (A) Schematic diagram illustrating the basic layout of the proximal DUT gene promoter
and promoter truncations cloned into the pGL3-Basic promoterless vector encoding the ﬁreﬂy luciferase gene. (B) Relative luciferase activity of
dUTPase promoter constructs (0.2mg) transiently transfected into the HCT116 p53
+/+ colon cancer cell line. (C) Schematic diagram illustrating the
site-speciﬁc triple Sp1 (pGL3:Sp1) and E2F mutant (pGL3:E2F) generated by site-directed mutagenesis as outlined in ‘Experimental Procedures’
section. (D) Relative luciferase activity of dUTPase promoter constructs (0.2mg) transiently transfected into the HCT116 p53
+/+ colon cancer cell
line. Transfections were performed as outlined in ‘Experimental Procedures’. Histogram bars represent mean SEM of three independent promoter
experiments.
 P<0.05,
  P<0.01,
   P<0.001; NS, not signiﬁcant.
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competitor oligonucleotides were incubated for 10min at
room temperature with Sp1 before the addition of labeled
probe. Sequences of the oligonucleotides were as follows:
DUT Sp1, 50-GGG CGG TGG GTG GGG CGG GGC
TGG CGG G-30; DUT Sp1,5 0-GTT CGG TGG GTG
GTT CGG GGC TGG CTT G-30.
RESULTS
Functional analysis ofthe dUTPase promoter
Due to the critical role of dUTPase in maintaining geno-
mic stability, the aberrant expression observed in neoplas-
tic tissues and the reported role of dUTPase in resistance
to chemotherapy, we sought to elucidate the transcrip-
tional mechanisms driving dUTPase gene expression. We
previously performed a computational sequence anal-
ysis of the 50 region of the human dUTPase gene and
identiﬁed putative binding sites for NFk-B, Sp1 and E2F
(15) (Supplementary Figure 1A). The presence of Sp1- and
E2F-binding sites is consistent with the hypothesis that the
dUTPase promoter is regulated in a cell-cycle-dependent
manner (31). However, to date there have been no studies
investigating the in vivo regulation of human dUTPase
at the promoter level. To address this, we ﬁrst sought to
determine the basal DNA regulatory elements of the
dUTPase promoter that are required for expression.
We utilized a luciferase-based system employing the
pGL3-Basic promoterless vector and sub-cloned deletion
mutant fragments targeting the putative E2F- and Sp1-
binding sites reported to be critical for S-phase gene
expression. We generated a series of four dUTPase pro-
moter truncations ranging from the designated ‘full
length’ (pGL3:FL) which incorporates the 1.231kb prox-
imal promoter upstream of the DUT-N transcriptional
start site, to the extensive truncation mutant pGL3:65
(Figure 1A) and analyzed luciferase expression in the
HCT116 p53
+/+ colon cancer cell line model. Truncation
of the pGL3:FL to the pGL3:608 resulted in an insignif-
icant decrease of 1.22-fold in promoter activity, suggesting
that the 50 region of the proximal dUTPase promoter may
contain relatively minor positive regulatory elements
(Figure 1B). A signiﬁcant reduction in promoter activity
of 2-fold was observed between the pGL3:608 and the
pGL3:162 which diﬀer by the consensus NFk-B-binding
site. A 2.9-fold reduction was observed when the
pGL3:162 was truncated to the pGL3:65 to exclude the
triple Sp1 sites. The pGL3:65 that contains only the E2F
site demonstrated a signiﬁcant 7.2-fold reduction in luci-
ferase activity compared to the pGL3:FL. Of note, the
activity of pGL3:65 remained 3.4-fold higher than the
pGL3-Basic promoterless vector (Figure 1B). These data
suggest that consensus sequences for NFk-B, E2F and to a
greater extent Sp1 may positively contribute to dUTPase
promoter activity.
Identification oftranscription factorsinvolved in
dUTPase gene expression
Sp1 and E2F family members are known to be key regu-
lators of S-phase gene promoters (32). Having identiﬁed
the region of the DUT gene promoter containing the
Sp1 and E2F transcription sites to be associated with posi-
tive regulation, we sought to determine the relative contri-
butions of both Sp1 and E2F consensus sequences to
dUTPase promoter activity. We utilized site-directed
mutagenesis of the pGL3:FL to disrupt the triple Sp1
(pGL3:Sp1) and E2F sites (pGL3:E2F) by double
nucleotide substitution within each respective site to gen-
erate mutant dUTPase luciferase constructs (Figure 1C
and Supplementary Figure 1B). We transiently transfected
the pGL3:FL, pGL3:Sp1 and the pGL3:E2F into the
HCT116 p53
+/+ cells and analyzed their basal promoter
activity. Mutation of the triple Sp1 sites decreased
dUTPase promoter activity 1.7-fold while disruption of
the E2F site resulted in a 2.6-fold reduction in promoter
activity when compared to the pGL3:FL (Figure 1D). This
data further establish and conﬁrms the role of Sp1 and E2F
sites as positive regulators of dUTPase promoter activity.
The role ofSp1 indUTPase gene expression
Elevated intratumoral expression of Sp1 is reported to
increase expression of genes that promote tumor pro-
cesses including progression and angiogenesis (33).
It is therefore plausible that dysregulation of Sp1 may
contribute to increased expression of dUTPase that is
observed in tumor tissues. In order to accurately deter-
mine the contribution of Sp1 to basal promoter activity,
we utilized the well-characterized Sp1-deﬁcient Drosophila
SL2 cells as a useful model for analyzing the inﬂuence of
Sp1-driven promoters in an Sp1-deﬁcient background
(32). The pGL3-Basic promoterless vector was subse-
quently co-transfected with the EV and pPac-Sp1 expres-
sion construct, both resulting in minimal luciferase
activity. Co-transfection of the pGL3:FL with pPac0
resulted in no signiﬁcant promoter activity when com-
pared to the co-transfection with pGL3-Basic. However,
co-transfection of pGL3:FL and pPac-Sp1 resulted in a
45-fold increase in luciferase activity (Figure 2A). These
data demonstrate that the dUTPase promoter requires
Sp1 for basal activity and is also highly responsive to
Sp1-mediated transcription in an Sp1-deﬁcient model.
Having conﬁrmed that the dUTPase promoter is
responsive to Sp1 in an Sp1-null background, we extended
these studies to the HCT116 p53
+/+ cells and tested the
eﬀect of Sp1 overexpression on the dUTPase promoter.
Western blot analysis demonstrated a physiologically
relevant 2-fold increase in Sp1 protein expression follow-
ing transfection with the pN3-Sp1 expression construct
(Figure 2B). Importantly, Sp1 overexpression did not
induce the pGL3-Basic control discounting any possible
non-speciﬁc eﬀects. Co-transfection of the pGL3:FL with
the pN3-Sp1 construct resulted in a 5.6-fold increase in
luciferase activity compared to the pN3-EV. We also
tested the Sp1-responsiveness of the promoter truncations
and demonstrate that the pGL3:608 truncation is signiﬁ-
cantly less responsive to Sp1-mediated activation than the
pGL3:FL (3.9-fold compared to 5.6-fold respectively),
further suggesting that the 50 region from –608 to –1231
may contain some Sp1-responsive elements. In addition,
the pGL3:65 containing only the E2F site was induced
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also mediate dUTPase promoter activation indirectly
through E2F consensus sequences (Figure 2B). However,
Sp1 overexpression resulted in only a modest increase in
luciferase activity of the pGL3:Sp1 which did not reach
statistical signiﬁcance (data not shown). These data would
suggest that the eﬀects of Sp1 overexpression were primar-
ily limited to the identiﬁed triple Sp1 sites.
To conﬁrm the role of Sp1 in dUTPase transcription, we
utilized Stealth
TM RNAi employing two siRNA duplexes
targeting the Sp1 mRNA. Transfection with the Sp1-
targeted siRNA resulted in knockdown of Sp1 as measured
by western blotting at 72h. Importantly dUTPase protein
expression was also markedly reduced at 72h in cells trans-
fected with Sp1-targeted siRNA when compared to mock-
and scrambled control-transfected cells. In addition, deple-
tion of Sp1 also signiﬁcantly attenuated the activity of
the dUTPase full-length promoter by >5-fold in HCT116
p53
+/+ cells (Figure 2C).
To further conﬁrm that Sp1 and E2F play a role in
driving dUTPase expression in vivo we utilized a highly
sensitive and quantitative approach combining ChIP
with qPCR and a primer set spanning the triple Sp1 and
E2F sites in the dUTPase promoter. We successfully
Figure 2. The role of Sp1 in dUTPase gene expression. (A) Relative luciferase activity of dUTPase full-length promoter (pGL3:FL) and pGL3-Basic
EV (0.2mg) co-transfected with pPac0 and pPac-Sp1 (0.2mg) in Drosophila SL2 cells. (B) Western blot demonstrating overexpression of Sp1 from
corresponding promoter lysates following transfection of HCT116 p53
+/+ cells with pN3-EV or pN3-Sp1 (0.2mg), anti-b-actin was used to control
for loading; relative luciferase of dUTPase promoter constructs co-transfected with both pN3-EV and pN3-Sp1 (0.2mg) in HCT116 p53
+/+ cells,
numbers indicate fold-increase of pN3-Sp1 transfected cells compared to pN3-EV. Transfections were performed as outlined in ‘Experimental
Procedures’ Section. Histogram bars represent mean SEM of three independent promoter experiments. (C) Top: Western blot following transfec-
tion of HCT116 p53
+/+ cells with Lipofectamine only (Mock), 100nM scrambled control siRNA (Scr) and 100nM of Stealth
TM DuoPak siRNA
targeting Sp1 (Sp1) for 72h and probed with anti-dUTPase and anti-Sp1. Anti-b-actin was used to control for loading. Bottom: Relative luciferase
activity of dUTPase full length promoter (pGL3:FL) transfected (0.2mg) into HCT116 p53
+/+ cells in the presence of scrambled control siRNA or
Stealth
TM DuoPak Sp1-targeted siRNA, histogram bars represent mean SEM of three independent promoter experiments. (D) Chromatin immu-
noprecipitation demonstrating in vivo association of E2F-1, Sp1 and Ac-H3 with the dUTPase promoter during normal cellular proliferation,
visualized by semi-quantitative gel electrophoresis and qPCR using primers encompassing the E2F and Sp1 sites (–39 to –260) in the dUTPase
promoter as indicated in Figure 1A.
  P<0.01,
   P<0.001; NS, not signiﬁcant.
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11- and 21.5-fold, respectively, at the dUTPase promoter
when compared to non-speciﬁc rabbit IgG controls and
normalized to input DNA. Acetyl-H3 (Ac-H3), an indica-
tor of active gene transcription was employed as a positive
control and demonstrated a highly signiﬁcant 200-fold
enrichment at the dUTPase promoter (Figure 2D).
These data provide the ﬁrst direct evidence that both
Sp1 and E2F-1 are actively associated with the dUTPase
promoter in vivo and that this region is subject to signiﬁ-
cant histone acetylation.
Ectopic p53 represses dUTPase promoter activity
Several reports have identiﬁed dUTPase as repressed fol-
lowing ectopic expression or induction of p53 (21,22) and
a p53-mutant transactivation gene target (24). Mutations
in the p53 tumor suppressor gene are reported in a wide
variety of cancers and in >50% of colon cancers (35).
Signiﬁcant evidence exists suggesting that tumor p53
status has direct impact on gene expression, tumor pro-
gression and response to chemotherapy (36). Given the
critical nature of dUTPase expression in modulating
response to the TS-inhibitor class of chemotherapeutics,
we sought to test whether dUTPase expression is modu-
lated by ectopic expression of both wild-type p53 (p53
WT)
and the hotspot R175H p53 mutant (p53
MUT). This is one
of the most common human tumor-derived mutant p53
proteins, harboring an Arg!His amino-acid substitution
resulting in a dominant gain-of-function and has been
reported to induce dUTPase in p53 null mouse ﬁbroblast
cells (24). We generated overexpression constructs using
the pCI-Neo vector and utilized the HCT116 p53
+/+ and
p53
–/– isogenic colon cancer cell lines to determine the
precise contribution of p53 on dUTPase promoter activ-
ity. For conﬁrmation purposes, p53 expression was veri-
ﬁed in the p53
+/+ cells and absence noted in the HCT116
p53
–/– by western blotting (Figure 3A).
To eliminate any eﬀects from endogenous p53, we
utilized the HCT116 p53
–/– cells. A titration using pCI-
Neo:p53
WT and pCI-Neo:p53
MUT constructs was per-
formed and indicated that a vector concentration of
0.2mg per transfection resulted in a physiological relevant
increase in p53 protein consistent with the level of induc-
tion in p53
+/+ cells at 24h post-DNA damage (data
not shown). Co-transfection of the pGL3:FL with pCI-
Neo:p53
WT and pCI-Neo:p53
MUT induced a physiologi-
cally relevant expression of the respective p53 proteins
detected by western blotting with the pCI-Neo EV control
demonstrating no detectable p53 protein (Figure 3B).
Co-transfection of the pGL3:FL with pCI-Neo: p53
WT
resulted in a 7-fold reduction in promoter activity when
compared to the pGL3:FL co-transfected with pCI-Neo
EV. In contrast, co-transfection of pGL3:FL with pCI-
Neo:p53
MUT resulted in a 1.9-fold increase in promoter
activity when compared to the corresponding EV control
(Figure 3C). We then analyzed the eﬀects of p53 overex-
pression in the p53
+/+ cells which contain endogenous
levels of p53 protein. Western blot analysis conﬁrmed
detection of basal p53 and similar levels of p53 overex-
pression in these cells compared to the p53
–/– cells
following transfection with the pCI-Neo:p53
WT and and
pCI-Neo:p53
MUT (Figure 3D). Co-transfection of the
pGL3:FL with pCI-Neo:p53
WT resulted in a 2.6-fold
reduction in promoter activity when compared to the
pGL3:FL co-transfected with pCI-Neo EV (Figure 3E).
In contrast, co-transfection of pGL3:FL with pCI-
Neo:p53
MUT resulted in a 3.8-fold increase in promoter
activity when compared to the corresponding EV control
(Figure 3E). These data indicate that ectopic expression of
wild-type p53 can repress dUTPase promoter activity and
that ectopic p53 mutant expression can induce dUTPase
promoter activity in the HCT116 p53 isogenic cell-line
models.
The effects of DNA damage-induced p53 on dUTPase
geneexpression
dUTPase expression is reported to be an important deter-
minant of sensitivity to chemotherapeutic agents that
target TS. Having determined that ectopic overexpression
of both p53
WT and p53
MUT have direct eﬀects on the
dUTPase promoter we sought to determine if DNA-
damage-induced p53 can directly modulate dUTPase
protein expression. We utilized the TS-targeted che-
motherapeutic agents 5-FU and FUdR, both of which
are reported to activate p53. In addition, we utilized oxa-
liplatin, a non-TS-directed DNA-damaging agent and the
primary 5-FU combination partner for the treatment of
colorectal cancer (37). Western blotting conﬁrmed the
induction of p53 at 24–72h in response to 5-FU, FUdR
and oxaliplatin treatment in the p53
+/+ cells (Figure 4A).
In response to 5-FU and FUdR, dUTPase protein expres-
sion remained unchanged until 72h post-treatment where
levels were only moderately reduced. Unexpectedly,
0.5mM oxaliplatin treatment signiﬁcantly downregulated
dUTPase at 48h post-treatment and by 72h dUTPase was
further reduced to undetectable levels by western blot ana-
lysis (Figure 4A). To investigate the contribution of
p53 expression to the novel observation that oxaliplatin
downregulates dUTPase, the HCT116 p53
+/+ and p53
–/–
isogenic cell lines were utilized. Western blot analysis
demonstrated that p53 was markedly induced in the
p53
+/+ cells but was not detected or induced in the
p53
–/– cells following treatment with 1mM oxaliplatin. In
response to oxaliplatin, dUTPase expression and enzy-
matic activity was signiﬁcantly downregulated 2- and
5-fold in the p53
+/+ cells at 48 and 72h, respectively.
No modulation of expression or activity was detected in
the p53
–/– cells at 48 or 72h (Figure 4B). This data sug-
gests that p53 or a downstream p53-target pathway is
responsible for the downregulation of dUTPase protein
expression following oxaliplatin treatment.
p53-mediated downregulation ofdUTPase by oxaliplatin is
induced throughatranscriptional mechanism
It has been reported that proteins involved in cell-cycle
progression and DNA synthesis are acutely downregu-
lated in an atypical manner following exit from cell-cycle
phases or following induction of DNA damage-induced
cell cycle arrest by mechanisms such as ubiquitination
and proteasomal degradation (38,39). To conﬁrm that
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protein was due to direct transcriptional repression
and not post-transcriptional mechanisms or protein stabi-
lity, we transfected the dUTPase full-length (pGL3:FL)
promoter construct into the HCT116 p53
+/+ and p53
–/–
isogenic cells and analyzed the eﬀects of oxaliplatin.
In the p53
+/+ cells, oxaliplatin potently attenuated activ-
ity of the pGL3:FL promoter by 5-fold with only a
modest reduction of 1.5-fold in p53
–/– cells (Figure 5A).
Mithramycin A, a speciﬁc inhibitor of Sp1-driven gene
expression that functions by binding to, and inhibit-
ing transcription from GC-rich promoters (33,34) was
utilized as a positive control and potently attenuated
dUTPase promoter activity by 3.5- and 10-fold in both
the p53
+/+ and p53
–/– isogenic cells respectively, consis-
tent with inhibiting Sp1-mediated dUTPase promoter
activity.
To further investigate the role of p53 in the transcrip-
tional downregulation of dUTPase, we employed the
Plexor
TM multiplex qPCR platform to simultaneously
analyze mRNA expression of both dUTPase and an addi-
tional S-phase gene and chemotherapeutic target TS.
Analysis of dUTPase mRNA in the p53
+/+ cells demon-
strated that following treatment with 1mM oxaliplatin,
dUTPase mRNA was downregulated 2.5- and >3-fold
at 24 and 48h when compared to respective time-matched
controls. In the p53
–/– cells, dUTPase mRNA was not
signiﬁcantly modulated by oxaliplatin at 24 or 48h when
compared to their respective time-matched control
(Figure 5B). Simultaneous analysis of TS mRNA demon-
strated a modest but signiﬁcant downregulation at 24h in
both p53
+/+ and p53
–/– cells when compared to the 24h
time-matched control. The oxaliplatin-induced downregu-
lation of TS was not statistically signiﬁcant diﬀerent
between the p53
+/+ and p53
–/–cells (Figure 5C). These
data conﬁrm that p53 expression plays a signiﬁcant role
in the oxaliplatin-induced transcriptional suppression of
dUTPase mRNA but not TS mRNA.
Figure 3. Ectopic p53 represses dUTPase promoter activity. (A) Western blot probed with anti-p53, anti-p21 conﬁrming p53 expression in
HCT116 p53
+/+ cells and absence of expression in HCT116 p53
–/– cells. HCT116 p21
–/– cells were included in this Western analysis for direct
comparative purposes, anti-b-actin was used to control for loading. (B) Western blot demonstrating equivalent ectopic expression of wild-type
p53 and mutant p53 protein following transient transfection with of pCI-Neo:p53
WT and pCI-Neo:p53
MUT (0.2mg) in the p53
–/– cell line.
(C) Fold-change in luciferase activity of dUTPase full-length (pGL3:FL) promoter construct (0.2mg) co-transfected with pCI-Neo:p53
WT and
pCI-Neo:p53
MUT (0.2mg) in the p53
–/– cell line. (D) Western blot demonstrating equivalent ectopic expression of wild-type p53 and mutant p53
protein following transient transfection with pCI-Neo:p53
WT and pCI-Neo:p53
MUT (0.2mg) in the HCT116 p53
+/+ cell line. (E) Fold-change in
luciferase activity of dUTPase full length (pGL3:FL) promoter construct (0.2mg) co-transfected with pCI-Neo:p53
WT and pCI-Neo:p53
MUT (0.2mg)
in the p53
+/+ cell line. All transfections were performed as outlined in ‘Experimental Procedures’ Section. Histogram bars represents mean SEM of
three independent promoter experiments.
 P<0.05,
  P<0.01,
   P<0.001.
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atypical protein turnover as a result of oxaliplatin-induced
cell-cycle arrest, we overexpressed dUTPase using the
pTre-Tight:DUT-N construct under the control of a
DOX-repressive minimal CMV promoter and treated
cells with oxaliplatin and analyzed dUTPase protein
expression and catalytic activity. Following overexpres-
sion, dUTPase protein and enzyme activity was increased
approximately 4-fold in the absence of DOX when
compared to an identical transfection in the presence of
0.5mg/ml DOX where ectopic expression was repressed.
When cells with basal dUTPase expression were treated
with 1mM oxaliplatin for 48h, accumulation of p53 was
conﬁrmed and a >2-fold downregulation in dUTPase pro-
tein and activity was observed compared to the respective
untreated control by western blot analysis. Cells overex-
pressing dUTPase from the ectopic minimal CMV pro-
moter also demonstrated p53 accumulation following
oxaliplatin treatment, with dUTPase expression levels
and catalytic activity demonstrating no signiﬁcant diﬀer-
ence in the presence and absence of 1mM oxaliplatin
(Figure 5D). These data suggest that dUTPase protein
expressed from the ectopic promoter was not a target
for atypical turnover, decreased stability or transcriptional
suppression by oxaliplatin treatment.
p53-mediated downregulation of dUTPase
does notrequire p21
Previous studies have demonstrated that p53-mediated
induction of the cell-cycle inhibitor p21 following
genotoxic stress resulted in repression of a number of
genes (40,41). We therefore used the HCT116 p21
–/–
cells, possessing p53
WT but lacking p21 protein to investi-
gate the possible inﬂuence of p53-mediated transactivation
of p21 on dUTPase promoter activity and gene expres-
sion. Western blot analysis previously conﬁrmed the
expression of p53 but lack of expression of p21 in these
cells (Figure 3C). Western blot analysis conﬁrmed similar
levels of p53 overexpression in these cells as the p53
+/+
and p53
–/– cells following transfection with the pCI-
Neo:p53
WT and pCI-Neo:p53
MUT (Figure 6A). We
utilized the pGL3:FL dUTPase promoter construct and
analyzed the eﬀects of wild type and mutant p53 expres-
sion on luciferase activity. Co-transfection of the
pGL3:FL with pCI-Neo:p53
WT resulted in 5-fold reduc-
tion in luciferase activity. Interestingly, co-transfection
of pGL3:FL with the pCI-Neo:p53
MUT resulted in a
3.65-fold induction in luciferase activity similar to results
obtained in the p53
+/+ cells (Figure 6B).
The ability of DNA-damage-induced p53 to repress the
dUTPase promoter in the absence of p21 induction was
subsequently analyzed. Following treatment with oxali-
platin, the pGL3:FL promoter was repressed 5-fold in
the p21
–/– cells which is identical to the observed repres-
sion in the HCT116 p53
+/+ cells. Mithramycin A was
used as a positive control and signiﬁcantly suppressed
the pGL3:FL promoter activity 20-fold (Figure 6C). To
further establish a direct mechanism of transcriptional
repression of dUTPase in the absence of p21, we utilized
the Plexor
TM multiplex qPCR and analyzed dUTPase
and TS mRNA expression following treatment with
Figure 4. The eﬀects of DNA damage-induced p53 on dUTPase gene expression. (A) Representative western blot showing timecourse following
treatment with the chemotherapeutic agents 5-FU (5mM), FUdR (1mM) and oxaliplatin (0.5mM), probed with anti-p53 and anti-dUTPase, anti-b-
actin was used to control for loading. (B) Representative western blot in HCT116 p53
+/+ and p53
–/– isogenic cells following treatment with 1mM
oxaliplatin for 48 and 72h. Membrane was probed with anti-p53, anti-dUTPase and anti-b-actin was used to control for loading; histogram represents
corresponding cell lysates subjected to dUTPase catalytic activity assay with oxaliplatin-treated samples expressed as a percentage of appropriate
untreated time-matched controls set at 100%, bars represents mean SEM from two replicates.
  P<0.01,
   P<0.001; NS, not signiﬁcant.
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resulted in a >2-fold reduction in dUTPase mRNA.
A small but signiﬁcant reduction in TS mRNA was
observed in the p21
–/– cells consistent with the p53
+/+
and p53
–/– isogenic cells (Figure 6D). Finally, western
blotting conﬁrmed that dUTPase protein expression was
downregulated in the p21
–/– cells following treatment with
1mM oxaliplatin at 48h in a manner consistent with
the p53
+/+ cells (Figure 6E). These data suggest that
the oxaliplatin-induced transcriptional repression of
dUTPase is independent of the p53-transactivation
target p21 and is more likely a direct transcriptional
eﬀect of p53 expression.
Oxaliplatin-induced repression ofthe dUTPase promoter
requires functionalSp1sites
Reports suggested that the transcriptional repression of
p53 can be exerted either through direct binding of p53
protein or via its sequestering of transcription factors
required for promoter activity. To investigate the down-
regulation of dUTPase in response to oxaliplatin treat-
ment, we utilized ChIP in conjunction with qPCR to
analyze changes at the dUTPase promoter. This approach
allows for quantitative analysis of the target region of
the dUTPase promoter by normalizing DNA immunopre-
cipated (IP) with the antibody of interest directly to
control IgG IP DNA with a subsequent calibration
Figure 5. p53-mediated downregulation of dUTPase by oxaliplatin is induced through a transcriptional mechanism. (A) Fold-change in luciferase
activity of dUTPase full-length promoter (pGL3:FL) following transfection (0.2mg) in HCT116 p53
+/+ and p53
–/– isogenic cells and treatment with
1mM oxaliplatin and 100nM mithramycin A compared to pGL3:FL untreated control set at 1. (B) qPCR analysis of dUTPase mRNA in HCT116
p53
+/+ and p53
–/– isogenic cells following treatment with 1mM oxaliplatin for 24 and 48h compared to time-matched controls set at 100%,
histogram bars represents mean SEM of three independent experiments. (C) qPCR analysis of TS mRNA in HCT116 p53
+/+ and p53
–/– isogenic
cells following treatment with 1mM oxaliplatin for 24h compared to time-matched control set at 100%, histogram bars represents mean SEM of
three independent experiments. (D) Western blot following transfection of HCT116 pTet-oﬀ cells with pTre-Tight:DUT-N (1mg) showing increased
expression of dUTPase in the absence of DOX (induced) and basal expression in the presence of 0.5mg/ml DOX (basal) and subsequent treatment
with 1mM oxaliplatin for 48h. Anti-p53 was used to conﬁrm p53 induction and anti-b-actin to control for loading; histogram represents correspond-
ing cell lysates subjected to dUTPase catalytic activity assay with treated samples expressed as a percentage of untreated control set at 100%, bars
represents mean SEM from two independent replicates.
 P<0.05,
   P<0.001; NS, not signiﬁcant.
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speciﬁc antibody binding and variations in input DNA
concentration and allows for sensitive quantiﬁcation of
alterations at the dUTPase promoter in response to
drug treatment. Following treatment with 1mM oxalipla-
tin and 100nM mithramycin A for 12h, we performed
ChIP analysis using antibodies against Sp1, E2F-1,
Ac-H3 and p53 in HCT116 p53
+/+ cells and compared
to untreated controls. We successfully detected basal
Ac-H3, E2F-1, Sp1 and p53 enrichment at the dUTPase
promoter compared to the IgG control in the region
containing the Sp1 and E2F consensus sequences ( 39
to  260).
Following treatment with 100nM mithramycin A,
Ac-H3 enrichment was reduced 2-fold consistent with
decreased gene transcription whereas Sp1 enrichment
was decreased 2.4-fold consistent with mithramycin A dis-
placing Sp1at the GC-rich dUTPase promoter. E2F-1
enrichment was not modulated in response to mithramy-
cin A. Signiﬁcantly, enrichment of the tumor suppressor
p53 remained unchanged in mithramycin A treated cells
(Figure 7A). Treatment with oxaliplatin resulted in a sig-
niﬁcant 2-fold reduction in Sp1 accompanied by a modest
decrease in E2F-1 and Ac-H3 enrichment at the dUTPase
promoter. Signiﬁcantly, enrichment of p53 was increased
2.3-fold at the dUTPase promoter following treatment
Figure 6. p53-mediated downregulation of dUTPase does not require p21. (A) Western blot demonstrating equivalent and physiologically relevant
ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with pCI-Neo:p53
WT and pCI-Neo:p53
MUT (0.2mg) in
the p21
–/– cell line. (B) Fold-change in luciferase activity of dUTPase full length (pGL3:FL) promoter construct (0.2mg) co-transfected with
pCI-Neo:p53
WT and pCI-Neo:p53
MUT (0.2mg) in the p21
–/– cell line. (C) Fold-change in luciferase activity of dUTPase full-length promoter
(pGL3:FL) (0.2mg) following treatment with 1mM oxaliplatin and 100nM mithramycin A compared to pGL3:FL untreated control set at 1 in
HCT116 p21
–/– cells. All histogram bars represents mean SEM of three independent promoter experiments, transfections were performed as
outlined in ‘Experimental Procedures.’ Numbers on histograms indicate fold-change compared to pGL3:FL. (D) qPCR analysis of dUTPase and
TS mRNA in HCT116 p21
–/– cells following treatment with 1mM oxaliplatin for 24h compared to time-matched control set at 100%. (E) Western
blot in HCT116 p21
–/– cells following treatment with 1mM oxaliplatin for 48h. Membrane was probed with anti-p53 and anti-dUTPase, anti-b-actin
was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with oxaliplatin-treated
samples expressed as a percentage of appropriate untreated time-matched controls. Histogram bars represents mean SEM from two independent
replicates,
 P<0.05,
  P<0.01,
   P<0.001.
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(Figure 7A). In an attempt to identify the p53-responsive
element in the dUTPase promoter, we subsequently trans-
fected the HCT116 p53
+/+ cells with the dUTPase Sp1
and E2F site-mutant promoter constructs and compared
the repression by oxaliplatin to the full–length construct.
Importantly, these site mutant constructs retained signiﬁ-
cant transcriptional activity in HCT116 cells (Figure 1D).
The full-length promoter was repressed 5-fold by oxali-
platin. The E2F site-mutant was repressed by oxaliplatin
Figure 7. Oxaliplatin-induced, p53-mediated repression of dUTPase is mediated through Sp1 sites and results in the accumulation of dUTP.
(A) Chromatin immunoprecipitation demonstrating in vivo alterations in Sp1 and p53 enrichment at the dUTPase promoter following 12h treatment
with 1mM oxaliplatin in HCT116 p53
+/+ cells. qPCR was performed using primers encompassing the E2F and Sp1 sites in the dUTPase promoter
from  39 to  260 as indicated. Histogram bars represent mean SE from two independent immunoprecipitations analyzed in triplicate by qPCR.
(B) Fold-change in luciferase activity of dUTPase promoter constructs (0.2mg) treated with 1mM oxaliplatin compared to untreated control set at 1,
histogram bars represents mean SE from three independent promoter experiments. (C) Growth inhibition of HCT116 p53
+/+ cells treated with
5-FU (0.5mM), FUdR (0.1mM) and oxaliplatin (0.5mM) and combinations. Histogram represents the mean SEM fraction of cells aﬀected (FA)
following three independent 72h incubations. (D) Western blot following treatment with 5-FU, FUdR and combinations for 48h in HCT116 p53
+/+
cells, membrane was probed with anti-dUTPase, anti-b-actin was used to control for loading; histogram represents corresponding cell lysates
subjected to dUTPase catalytic activity assay with treated samples expressed as a percentage of appropriate untreated time-matched control set
at 100%. (E) dUTP accumulation assay measuring intracellular dUTP as a percentage of the total dUTP/TTP pool in HCT116 p53
+/+ cells
following treatment with the TS-inhibitors 5-FU (0.5mM), FUdR (0.1mM) for 24h and oxaliplatin (0.5mM) for 24 and 48h. Combinations were
performed by incubating with oxaliplatin (0.5mM) for 24h, media was removed, cells were washed and re-incubated in media containing the
appropriate TS-inhibitor or the microtubule-stabilizing agent paclitaxel (20nM) as a non-TS-directed control. Histogram bars represents
mean SEM from two independent experiments performed in duplicate. y indicates that dUTP was not detected in cell extracts.
 P<0.05,
  P<0.01,
   P<0.001; NS, not signiﬁcant.
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tely abrogated the oxaliplatin-induced promoter repres-
sion (Figure 7B) suggesting that p53 is acting on the
region of the promoter containing the Sp1 sites. To con-
ﬁrm that the mutations within the pGL3:Sp1 construct
eﬃciently impair Sp1 binding, we performed EMSA anal-
ysis. Using a dUTPase
32P-labelled probe encompassing
the triple Sp1-binding sites (–64 to –91), we demonstrate
binding of recombinant Sp1 (rhSp1) to both this sequence
and a control Sp1 consensus oligo. However, a mutant
probe corresponding to the Sp1 site mutations within
the pGL3:Sp1 construct failed to compete for binding
with rhSp1 (Supplementary Figure 3). This data supports
the hypothesis that repression of the dUTPase promoter
by oxaliplatin requires functional Sp1 sites.
Oxaliplatin induces accumulation of dUTP alone and in
combination withTS-inhibitors in HCT116 p53
+/+cells
Oxaliplatin is clinically approved for the treatment of
colon cancer and is primarily used in combination
with 5-FU or capecitabine where these drugs demonstrate
synergistic anti-tumor activity (37). Given the novel
observation that a clinically relevant concentration of
oxaliplatin (0.5mM, Figure 4A) can acutely downregulate
dUTPase protein in a p53-dependent manner in a
colon cancer model, we sought to test the possible clinical
implications of this by measuring the accumulation of
dUTP, a downstream cytotoxic event induced by che-
motherapeutics that inhibit TS. We utilized 5-FU whose
eﬀects include TS-inhibition, and incorporation of ﬂuori-
nated nucleotides into DNA and RNA and the more
speciﬁc TS-inhibitor FUdR which induces only DNA-
directed eﬀects. First, we conﬁrmed that the treatment
of HCT116 p53
+/+ cells with oxaliplatin and either
5-FU or FUdR for 72h resulted in enhanced growth inhi-
bition (Figure 7C) and resulted in downregulation of
dUTPase protein and enzyme activity (Figure 7D). To
verify that the eﬀects on dUTP accumulation with drug
combinations were a speciﬁc eﬀect of TS-inhibition, we
included the microtubule-stabilizing agent paclitaxel as
a non-TS-directed control agent. Intracellular dUTP was
measured using a polymerase-based nucleotide pool assay
which detects both TTP and dUTP from cell extracts,
with subsequent incubation with recombinant dUTPase
indicating the contribution of dUTP as a percentage
of the total dUTP/TTP detected. No dUTP was detected
in untreated control cells or following treatment with the
sub-cytotoxic concentrations of 0.1mM FUdR and 0.5mM
5-FU at 24h. Following treatment with 0.5mM oxaliplatin
alone for 24h, there was no detectable dUTP in cell
extracts (Figure 7E). However, treatment with 0.5mM
oxaliplatin alone for 48h resulted in the signiﬁcant accu-
mulation of dUTP. Speciﬁcally, within the total dUTP/
TTP pool, 15.4% was dUTP, correlating with the acute
reduction in dUTPase expression and activity previously
noted. When cells were treated with oxaliplatin for 24h
followed by 0.1mM FUdR or 0.5mM 5-FU for a further
24h, dUTP accumulation was signiﬁcantly increased
to 28% and 25% respectively of the total dUTP/TTP
pool. To conﬁrm that this eﬀect was a direct result of
downregulation of dUTPase followed by subsequent TS
inhibition, we used the control combination of 0.5mM
oxaliplatin for 24h followed by the non-TS-directed
microtubule stabilizing drug paclitaxel (20nM) for 24h.
This resulted in the detection of <3% of dUTP in the
total dUTP/TTP, and would suggest that the increase in
dUTP accumulation observed with 5-FU/FUdR and
oxaliplatin combinations was a direct result of the TS
metabolic blockade in the absence of an active dUTPase
enzyme (Figure 7E). These data suggest that suppres-
sion of dUTPase by oxaliplatin may enhance the
ﬂuoropyrimidine-induced accumulation of dUTP and
may contribute to the synergistic interaction between
these agents.
DISCUSSION
Expression of dUTPase in malignant cells demonstrates
signiﬁcant variation, both in total expression and subcel-
lular localization which may account for diﬀerences in
clinical response to the TS-inhibiting class of chemother-
apeutics (10). Therefore, elucidating the molecular basis
for variable dUTPase expression is of interest from both
a basic science and clinical perspective. Using promoter
analysis in HCT116 p53
+/+ colon cancer cells, the region
containing the E2F and triple Sp1 site was found to be
suﬃcient for driving DUT-N promoter activity (Figure 1A
and B). Site-directed mutagenesis of the E2F and Sp1 sites
clearly demonstrated that both transcription factors posi-
tively contribute to basal promoter activity (Figure 1C
and D). We also report that the dUTPase promoter is
highly responsive to Sp1 overexpression in HCT116
colon cells and silent in the absence of Sp1 and responsive
to Sp1 expression in Sp1-deﬁcient Drosophila SL2 cells
(Figure 2A). Furthermore, knockdown of Sp1 resulted
in the downregulation of dUTPase protein expression
and signiﬁcantly attenuated dUTPase promoter activity
(Figure 2C). Finally we conﬁrmed the presence of both
Sp1 and E2F-1 transcription factors at the proximal
dUTPase promoter in vivo using ChIP and qPCR
(Figure 2D). Interestingly, dysregulation of both Sp1
(33,42,43) and E2F-1 (44–47) are widely observed follow-
ing neoplastic transformation and are reported to contri-
bute to a variety of tumor processes including progression,
drug resistance, angiogenesis and metastasis. It is there-
fore likely that dysregulation of E2F-1 and Sp1 expression
may contribute to the wide variation in dUTPase expres-
sion levels observed in tumor tissues (10,16,17).
Initial reports identiﬁed dUTPase mRNA as modulated
by both mutant and wild-type p53 (22,24). However, the
precise mechanism by which wild-type p53 exerts its
repressive eﬀects on dUTPase has not been described.
To our knowledge, this report provides the ﬁrst evidence
demonstrating that dUTPase is directly modulated at the
transcriptional level by an in vivo promoter association
with p53. Introduction of p53
WT resulted in signiﬁcant
repression of the dUTPase promoter (Figure 3C and E).
Interestingly, the level of repression in the HCT116 p53
–/–
cells was signiﬁcantly greater following introduction
of p53
WT when compared to the HCT116 p53
+/+ cells,
suggesting that expression of p53
WT already exerts a
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HCT116 p53
+/+ cells. This is further supported by the
observation that when the p53
MUT is introduced into
the p53
+/+ cells, the promoter activity is induced to a
much greater extent than the p53
–/– cells. This phenom-
enon may be exacerbated due to the artiﬁcial nature of
the luciferase system, but would indicate the disruption
of an unknown mediator involved in dUTPase promoter
regulation by the dysregulated interactions of p53
MUT.
This observation has previously been noted in the TSP50
gene which is negatively regulated by p53, where the
authors reported that introduction of mutant p53 signiﬁ-
cantly increased the TSP50 promoter activity in the three
cell lines containing p53
WT (48). These data would further
suggest that tumoral p53 status and mutation may be
important regulators of dUTPase expression and thus
may inﬂuence chemotherapeutic response.
It is important to consider that ectopic p53 expression is
unlikely to accurately simulate p53 activation in response
to DNA damage which involves complex post-translation
modiﬁcations. We therefore utilized chemotherapeutic
agents used in the treatment of colorectal cancer which
are known to activate p53 including the DNA-damaging
agent oxaliplatin and the TS-inhibitors 5-FU and FUdR.
Both 5-FU and FUdR resulted in a modest downregula-
tion of dUTPase protein consistent with previous reports
(21,49) (Figure 4A). However, for the ﬁrst time, we iden-
tiﬁed oxaliplatin as a potent downregulator of dUTPase at
the promoter, mRNA and protein levels (Figure 4B and
5A). Treatment of the HCT116 p53
–/– cells with the same
clinically relevant doses of oxaliplatin failed to modulate
the dUTPase promoter or downregulate mRNA and pro-
tein expression, indicating a direct role for p53 or a p53-
target in the repression (Figure 4B, 5A and B). Moreover,
our ﬁndings indicate that this acute downregulation pre-
ceded complete cell cycle arrest with rapid repression of
the dUTPase promoter and downregulation of the mRNA
within 24h. Although both 5-FU and FUdR result in
similar levels of p53 induction, the cytotoxicity induced
by these agents is of a signiﬁcantly diﬀerent nature than
oxaliplatin. Speciﬁcally, 5-FU and FUdR are reported to
initiate rapid S-phase arrest which is associated with
thymidylate depletion as a result of TS-inhibition and is
independent of p53 (50). The induction of p53 in response
to 5-FU is reported to be a later event, possibly due to
aberrant detection of uracil and ﬂuoronucleotides in
synthesized DNA. Oxaliplatin binds with high aﬃnity to
GC-rich DNA forming bulky platinum adducts which
block DNA replication, activate p53 and stimulate the
nucleotide excision repair pathway (51). Importantly, oxa-
liplatin treatment in HCT116 cells was previously reported
to initiate a p53-dependent cell cycle arrest, indicating an
immediate role for p53 in mediating the cellular response
to oxaliplatin in the HCT116 colon cancer model (52).
A recent report directly compared the p53 response in
colon cancer cells treated with 5-FU compared to the
direct DNA-damaging agent doxorubicin. The authors
noted that 5-FU treatment did not accumulate p53 or
result in p53 phosphorylation until 24h post-treatment.
However, doxorubicin treatment resulted in rapid p53
induction through protein stabilization and noted that
p53 protein was both rapidly phosphorylated and acety-
lated within 4h of treatment (53). Furthermore, p53 sig-
naling is a complex pathway involving multiple post-
translational modiﬁcations which are speciﬁc to its subse-
quent functions which vary markedly from cell-cycle
arrest and DNA repair to apoptosis (54,55). Considering
that oxaliplatin is also a direct DNA-damaging agent, it is
possible that the mechanism of resultant p53 activation
and associated post-translational modiﬁcations are mark-
edly diﬀerent than those observed following treatment
with 5-FU and FUdR and this may account for the dif-
ference in the ability of these agents to repress dUTPase
gene expression. We also note that ectopic dUTPase pro-
tein expression from an exogenous CMV-driven promoter
was unaﬀected by oxaliplatin, discounting protein stability
or atypical turnover and supporting a direct transcrip-
tional eﬀect (Figure 5D). Simultaneous analysis of TS,
another classical S-phase gene revealed only a moderate
downregulation following oxaliplatin treatment indepen-
dent of p53 (Figure 5C), supporting the idea that the pre-
sence of a p53 responsive element is a key diﬀerence
between the regulation of TS and dUTPase.
Previous reports suggested that p53-mediated transacti-
vation of p21 was suﬃcient and necessary to exert the
negative gene regulation of p53 (40). By using a p21
HCT116 null isogenic cell line, we demonstrate that p21
is not required for the transcriptional repression of
dUTPase in response to oxaliplatin, further suggesting a
direct role for p53 (Figure 6). We subsequently conﬁrmed
the presence and enrichment of p53at the dUTPase prox-
imal promoter following treatment with oxaliplatin.
Importantly, this was accompanied by reductions in Sp1
and Ac-H3 (Figure 7A). Although the exact mechanism
by which p53 represses the dUTPase promoter is not clear,
these observations suggest that p53 interacts with the
dUTPase promoter transcriptional machinery in the
absence of a p53-speciﬁc cis element to suppress gene
expression. In support of our observations, additional
reports demonstrated p53-mediated transcriptional repres-
sion of the protective antioxidant enzyme manganese
superoxide dismutase and the anti-apoptotic molecule
MCL-1 in the absence of a p53 consensus site and demon-
strated this to be mediated through disruption of normal
transcription factor binding (56,57). Furthermore, the
DNA repair enzyme AP-endonuclease is repressed by
p53, in the absence of a cis element through interfering
with Sp1 binding (58). This model is supported by our
ﬁndings which demonstrated increased p53 and reduced
Sp1at the dUTPase promoter following oxaliplatin treat-
ment. Interestingly, treatment with mithramycin A, which
directly reduced Sp1 enrichment, did not show enrichment
for p53, suggesting that displacing Sp1 or additional
Sp-family members at the dUTPase promoter or inhibit-
ing additional Sp1-driven gene expression can abrogate
the promoter enrichment of p53. In support of this, our
observation that the triple Sp1 site-mutant construct,
which importantly still retained 50% transcriptional activ-
ity of the full-length construct, was not repressed by oxa-
liplatin and would further indicate that p53 is exerting its
repressive eﬀects through the region of the promoter
known to bind Sp1 (Figure 7B). Previous studies have
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scription factors in vivo including Sp1 (57,59) and with
histone deacetylase 1 (60) and repress transcription from
speciﬁc promoters. Importantly, it has also been demon-
strated that mutant p53 lacks the capacity to interact with
HDAC1 and repress transcription (60), representing
another possible mechanism for the p53-mutant induction
of dUTPase previously reported (24) and our observations
in this report showing p53-mutant induction of the
dUTPase promoter. Furthermore, the inability of
mutant forms of p53 to repress gene transcription may
contribute to associated chemoresistance by abrogating
apoptosis induced through repression of protective genes.
As a single agent, oxaliplatin has limited clinical activity
in colorectal cancer and is primarily used in combination
with 5-FU or capecitabine resulting in synergistic anti-
tumor activity (3,37,61). Attempts to deﬁne the molecular
basis for this synergistic interaction have demonstrated
that oxaliplatin induces modest suppression of both TS
mRNA and activity of the 5-FU catabolic enzyme dihy-
dropyrimidine dehydrogenase (DPD) (62,63). In the pre-
sent study, we conﬁrmed that oxaliplatin induced a
modest downregulation of TS mRNA independent of
p53 and p21. In addition, we provide the ﬁrst evidence
of a p53-dependent acute downregulation of dUTPase in
the HCT116 p53
+/+ colon cell line following treatment
with a clinically relevant dose of oxaliplatin. When oxali-
platin was combined with a TS-inhibitor, there was a sig-
niﬁcant increase in the accumulation of dUTP consistent
with downregulation of dUTPase and increased eﬀects of
TS-inhibition (Figure 7E). Targeted use of oxaliplatin in
tumors with elevated levels of dUTPase and wild-type p53
may represent a novel strategy for improving the thera-
peutic eﬃcacy of TS-directed agents and warrants further
investigation (Figure 8).
Additional genes with critical roles in cytoprotection
and survival including anti-apoptotic, oxidative stress
elimination and DNA repair genes have previously been
demonstrated to be repressed by p53, promoting the
hypothesis that the pro-apoptotic function of p53 is
mediated in part through transcriptional repression of
cytoprotective genes. It is therefore plausible that the
p53-mediated repression of dUTPase may enhance DNA
damage and represent one component in the commitment
to irreversible cell death and contribute to the tumor sup-
pressing functions governed by p53.
In conclusion, p53 plays a critical role in the transfor-
mation and progression of many human malignancies,
thus, the eﬀect of p53 on uracil–DNA metabolism may
increase our understanding of the complex regulatory
pathways governed by p53 and may assist in providing
more targeted chemotherapy. Our results have identiﬁed
and characterized a novel mechanism of p53-dependent
transcriptional regulation of an evolutionary conserved
and essential enzyme involved in regulating intracellular
uracil pools and maintaining genomic stability.
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